Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly

American Journal of Medicine

Volumn 104, Issue 5, 1998, Pages 439-444

  Cohen, Harvey Jay ^a   Crawford, Jeffrey ^a   Rao, Murali K ^a   Pieper, Carl F ^a   Currie, Mark S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; SERUM ALBUMIN;

AGAR GEL ELECTROPHORESIS; AGED; ARTICLE; ELDERLY CARE; ENVIRONMENTAL FACTOR; HEMOGLOBIN ANALYSIS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; SOCIOECONOMICS;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; DISEASE SUSCEPTIBILITY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MASS SCREENING; MULTIPLE MYELOMA; NORTH CAROLINA; PARAPROTEINEMIAS; PREVALENCE; SAMPLING STUDIES; SEX DISTRIBUTION;

EID: 0032076120     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00080-1     Document Type: Article

References (43)

1. 1. Gautier M, Cohen HJ. Multiple myeloma in the elderly. J Am Geriatr Soc. 1994;42:653-664.
2. 2. Kyle RA, Bayrd ED. The Monoclonal Gammopathies: Multiple Myeloma and Related Disorders. Springfield, Ill: Charles C Thomas; 1976:91-102;156-171;190-191.
3. 3. Kyle RA. Current concepts on monoclonal gammopathies. Aust NZ J Med. 1992;22:291-302.
4. 4. Fine JM, Lambin P, Lerous P. Frequency of monoclonal gammopathy (M-components) in 13,400 sera from blood donors. Vox Sang. 1972;23:336-343.
5. 5. Ligthart G, Radl J, Corberand J, et al. Monoclonal gammopathies in human aging: increased occurrence with age and correlation with health status. Mech Ageing Dev. 1990;52:235-243.
6. 6. Crawford J, Eye M, Cohen HJ. Evaluation of monoclonal gammopathies in the "well elderly." Am J Med. 1987;82:39-45.
7. 7. Radl J, Sepers JM, Skvaril F, et al. Immunoglobulin patterns in humans over 95 years of age. Clin Exp Immunol. 1975;22:84-90.
8. 8. National Cancer Institute Surveillance, Epidemiology and Endocrine Results (SEER) Program 1986. Data on Cancer Statistics 1973-1985. Bethesda, Md: National Cancer Institute; 1986.
9. 9. Cohen HJ. Multiple myeloma in the elderly. Clin Geri Med. 1985; 1(4):827-855.
10. 10. Axelsson U, Bachmann R, Hallen J. Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. Acta Med Scand. 1988;179:235-247.
11. 11. Kyle RA, Finkelstein S, Eleveback LR, et al. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood. 1972;40:719-724.
12. 12. Schwartz J. Multinational trends in multiple myeloma. Ann NY Acad Sci. 1990;609:215-224.
13. 13. Lewis DR, Pottern LM, Brown LM, et al. Multiple myeloma among blacks and whites in the United States: the role of chronic antigenic stimulation. Cancer Causes Control. 1994;5:529-539.
14. 14. Hernandez JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer. 1995;75(suppl):381-394.
15. 15. Bowden M, Crawford J, Cohen HJ, Noyama O. A comparative study of monoclonal gammopathies and immunoglobulin levels in Japanese and United States elderly. J Am Geriatr Soc. 1993;41:11-14.
16. 16. Singh B, Dudley AW, Kulig KA. Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and 1 woman in a hospital setting. J Lab Clin Med. 1990;116:785-789.
17. 17. Schechter GP, Shoff N, Chan C, et al. The frequency of monoclonal gammopathy of unknown significance in black and Caucasian veterans in a hospital population. In: Obrams GI, Potter M, eds. Epidemiology and Biology of Multiple Myeloma. Berlin: Springer-Verlag;1991:83-85.
18. 18. Cornoni-Huntley J, Ostfeld AM, Taylor JO, et al. Established populations for epidemiologic studies of the elderly: study design and methodology. Aging Clin Exp Res. 1993;5:27-37.
19. 19. Blazer DG, Burchett BM, Service C, George LK. The association of age and depression among the elderly: an epidemiologic exploration. J Gerontol Med Sci. 1991;46:M210-M215.
20. 20. Koessel SL, Theis MK, Vaughan TL, et al. Socioeconomic status and the incidence of multiple myeloma. Epidemiology. 1996;7:4-8.
21. 21. Fritschi L, Siemiatycki J. Lymphoma, myeloma and occupation: results of a case-control study. Int J Cancer. 1996;67:498-503.
22. 22. Pasqualetti P, Collacciani A, Casale R. Risk of monoclonal gammopathy of undetermined significance: a case-referent study. Am J Hematol. 1996;52:217-220.
23. 23. Hedrick SC. Assessment of functional status: activities of daily living. In: Rubenstein LZ, Wieland D, Berrabei R, eds. Geriatric Assessment Technology: The State of the Art. Milan: Editrice-Kurtis;1995: 51.
24. 24. Fillenbaum GG. Screening the elderly: a brief instrumental ADL measure. J Am Geriatr Soc. 1985;33:698-706.
25. 25. Cohen HJ, Pieper CF, Harris T, et al. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol Med Sci. 1997;52:M201-M208.
26. 26. McLaughlin JK, Linet MS, Stone BJ, et al. Multiple myeloma and occupation in Sweden. Arch Environ Health. 1988;43:7-10.
27. 27. Pearce NE, Smith AH, Howard JK, et al. Case-control study of multiple myeloma and farming. Br J Cancer. 1986;54:493-500.
28. 28. Baquet CR, Horm JW, Gibbs T, Greenwald P. Socioeconomic factors and cancer incidence among blacks and whites. J Natl Canc Inst. 1991;83:551-557.
29. 29. Johnston JM, Grufferman S, Bourguet CC, et al. Socioeconomic status and risk of multiple myeloma. J Epid Comm Health. 1985;39: 175-178.
30. 30. Pottern LM, Gart JJ, Nam J, et al. HLA and multiple myeloma among black and white men: evidence of a genetic association. Cancer Epidemiol Biomark Prev. 1992; 1:177-182.
31. 31. Cohen HJ. Monoclonal gammopathies: a model for neoplasia in older persons. In: Balducci L, ed. Geriatric Oncology. Philadelphia: JB Lippincott; 1992:92-96.
32. 32. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
33. 33. Axelsson U. A 20-year follow-up study of 64 subjects with M-components. Acta Med Scand. 1986;219:519-522.
34. 34. Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med. 1978;64:814-826.
35. 35. Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma: implications for progression to overt multiple myeloma. Hematol Oncol Clin North Am. 1997;11(1):71-87.
36. 36. Cao J, Hong CH, Rosen L, et al. Deletion of genetic material from a poly(ADP-ribose) polymerase-like gene on chromosome 13 occurs frequently in patients with monoclonal gammopathies. Cancer Epidemiol Biomark Prev. 1995;4:759-763.
37. 37. Cohen HJ, Bernstein RJ, Grufferman S. Role of immune stimulation in the etiology of multiple myeloma: a case control study. Am J Hematol. 1987;24:119-126.
38. 38. Cuzick J. Multiple myeloma. Cancer Surveys. 1994;19:455-474.
39. 39. Kyle RA, Robinson RA, Katzmann JA. The clinical aspects of biclonal gammopathies: review of 57 cases. Am J Med. 1981;71:999-1008.
40. 40. Herrinton LJ, Demers PA, Koepsell TD, et al. Epidemiology of the M-component immunoglobulin types of multiple myeloma. Cancer Causes Control. 1993;4:83-92.
41. 41. Bataille R, Jourdan M, Zhang X-G, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest. 1989;84: 2008-2011.
42. 42. Tienhaara A, Pulkki K, Mattila K, et al. Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. Br J Haematol. 1994;86:391-393.
43. 43. Ballester OF, Moscinski LC, Lyman GH, et al. High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood. 1994;83(7):1903-1908.